Morgan Stanley Castle Biosciences Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Castle Biosciences Inc stock. As of the latest transaction made, Morgan Stanley holds 167,588 shares of CSTL stock, worth $3.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

167,588

Previous 211,793 20.87%

Holding current value

$3.86 Million

Previous $4.24 Million 19.29%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$15.8 - $21.98 $698,439 - $971,625	-44,205 Reduced 20.87%	167,588 $3.42 Million
Q1 2025 May 15, 2025	SELL	$18.76 - $32.72 $1.78 Million - $3.1 Million	-94,884 Reduced 30.94%	211,793 $4.24 Million
Q4 2024 Feb 14, 2025	SELL	$26.52 - $34.67 $2.39 Million - $3.13 Million	-90,242 Reduced 22.74%	306,677 $8.17 Million
Q3 2024 May 14, 2025	BUY	$17.4 - $31.47 $2.57 Million - $4.64 Million	147,539 Added 59.16%	396,919 $11.3 Million
Q3 2024 Nov 14, 2024	BUY	$17.4 - $31.47 $2.57 Million - $4.64 Million	147,539 Added 59.16%	396,919 $11.3 Million
Q2 2024 May 14, 2025	SELL	$18.84 - $24.94 $1.08 Million - $1.43 Million	-57,297 Reduced 18.68%	249,380 $5.43 Million
Q2 2024 Oct 17, 2024	SELL	$18.84 - $24.94 $7.56 Million - $10 Million	-401,331 Reduced 61.68%	249,380 $5.43 Million
Q2 2024 Aug 14, 2024	SELL	$18.84 - $24.94 $7.56 Million - $10 Million	-401,331 Reduced 61.68%	249,380 $5.43 Million
Q1 2024 Oct 17, 2024	BUY	$18.06 - $25.3 $7.25 Million - $10.2 Million	401,331 Added 160.93%	650,711 $14.4 Million
Q1 2024 Aug 16, 2024	BUY	$18.06 - $25.3 $3.12 Million - $4.37 Million	172,676 Added 36.12%	650,711 $14.4 Million
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $3.12 Million - $4.37 Million	172,676 Added 36.12%	650,711 $14.4 Million
Q4 2023 Aug 16, 2024	BUY	$12.19 - $22.43 $2.79 Million - $5.13 Million	228,655 Added 91.69%	478,035 $10.3 Million
Q4 2023 Feb 13, 2024	BUY	$12.19 - $22.43 $5.36 Million - $9.86 Million	439,389 Added 1136.96%	478,035 $10.3 Million
Q3 2023 Nov 15, 2023	SELL	$13.28 - $20.3 $878,259 - $1.34 Million	-66,134 Reduced 63.12%	38,646 $652,000
Q2 2023 Aug 14, 2023	BUY	$11.66 - $26.0 $185,580 - $413,816	15,916 Added 17.91%	104,780 $1.44 Million
Q1 2023 May 15, 2023	BUY	$19.47 - $28.49 $594,730 - $870,255	30,546 Added 52.38%	88,864 $2.02 Million
Q4 2022 Feb 14, 2023	SELL	$18.08 - $30.0 $2.49 Million - $4.12 Million	-137,484 Reduced 70.22%	58,318 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $1.96 Million - $2.98 Million	86,863 Added 79.74%	195,802 $5.11 Million
Q2 2022 Oct 27, 2022	BUY	$16.0 - $45.99 $1.31 Million - $3.76 Million	81,797 Added 301.37%	108,939 $2.39 Million
Q2 2022 Aug 15, 2022	BUY	$16.0 - $45.99 $1.31 Million - $3.76 Million	81,797 Added 301.37%	108,939 $2.39 Million
Q1 2022 Oct 27, 2022	SELL	$33.17 - $46.98 $2.71 Million - $3.84 Million	-81,797 Reduced 75.09%	27,142 $1.22 Million
Q1 2022 May 13, 2022	SELL	$33.17 - $46.98 $522,659 - $740,263	-15,757 Reduced 36.73%	27,142 $1.22 Million
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $1.05 Million - $1.82 Million	-26,923 Reduced 38.56%	42,899 $1.84 Million
Q3 2021 Nov 15, 2021	BUY	$60.13 - $77.6 $4.2 Million - $5.42 Million	69,822 New	69,822 $4.64 Million

Others Institutions Holding CSTL

# of Institutions

167

Shares Held

27.2M

Call Options Held

Put Options Held

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $605M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account